Clinicopathological Characterization and Prognostic Implication of SMAD4 Expression in Colorectal Carcinoma

키워드

참고문헌 (52)

1. Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 68, pp.394~424 (2018)
2. Zhao M, "The role of TGF-beta", SMAD4 signaling in cancer, 2018, pp.14, 111~123
3. Schutte M., "DPC4", SMAD4 gene alterations in human cancer, and their functional implications, 1999, pp.10(Suppl 4), 56~59
4. Du Y, "Meta-analysis of the prognostic value of smad4 immunohistochemistry in various cancers", PLoS One, 9, pp.e110182~ (2014)
5. Wang JD, "Clinicopathological significance of SMAD4 loss in pancreatic ductal adenocarcinomas : a systematic review and meta-analysis", Oncotarget, 8, pp.16704~16711 (2017)
6. Kouvidou C, "Expression of Smad4 and TGF-beta2 in colorectal carcinoma", Anticancer Res, 26, pp.2901~2907 (2006)
7. Xu WQ, "Expression of TGFbeta1, TbetaRII and Smad4 in colorectal carcinoma", Exp Mol Pathol, 82, pp.284~291 (2007)
8. Bacman D, "TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma : a retrospective study", BMC Cancer, 7, pp.156~ (2007)
9. Isaksson-Mettaväinio M, "High SMAD4 levels appear in microsatellite instability and hypermethylated colon cancers, and indicate a better prognosis", Int J Cancer, 131, pp.779~788 (2012)
10. Voorneveld PW, "Evaluation of the prognostic value of pSMAD immunohistochemistry in colorectal cancer", Eur J Cancer Prev, 22, pp.420~424 (2013)
11. Kozak MM, "Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer", J Clin Pathol, 68, pp.341~345 (2015)
12. Yan P, "Reduced expression of SMAD4is associated with poor survival in colon cancer", Clin Cancer Res, 22, pp.3037~3047 (2016)
13. Jain S, "Association of overexpression of TIF1gamma with colorectal carcinogenesis and advanced colorectal adenocarcinoma", World J Gastroenterol, 17, pp.3994~4000 (2011)
14. Handra-Luca A, "SMAD4 protein expression and cell proliferation in colorectal adenocarcinomas", Virchows Arch, 459, pp.511~519 (2011)
15. 정유민, "The Smad4", PTEN Expression Pattern Predicts Clinical Outcomes in Colorectal Adenocarcinoma, 2018, pp.52(1), 37~44[DOI]
16. Oyanagi H, "SMAD4 alteration associates with invasive-front pathological markers and poor prognosis in colorectal cancer", Histopathology, 74, pp.873~882 (2019)
17. Wasserman I, "SMAD4 loss in colorectal cancer patients correlates with recurrence, loss of immune infiltrate, and chemoresistance", Clin Cancer Res, 25, pp.1948~1956 (2019)
18. Alhopuro P, "SMAD4 levels and response to 5-fluorouracil in colorectal cancer", Clin Cancer Res, 11, pp.6311~6316 (2005)
19. Boulay JL, "SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer", Br J Cancer, 87, pp.630~634 (2002)
20. Alazzouzi H, "SMAD4 as a prognostic marker in colorectal cancer", Clin Cancer Res, 11, pp.2606~2611 (2005)
21. Isaksson-Mettavainio M, "SMAD4", DPC4 expression and prognosis in human colorectal cancer, 2006, pp.26, 507~510
22. Mesker WE, "Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients", Cell Oncol, 31, pp.169~178 (2009)
23. Baraniskin A, "Prognostic value of reduced SMAD4 expression in patients with metastatic colorectal cancer under oxaliplatin-containing chemotherapy : a translational study of the AIO colorectal study group", Clin Colorectal Cancer, 10, pp.24~29 (2011)
24. Wang C, "High expression of COUP-TF II cooperated with negative Smad4 expression predicts poor prognosis in patients with colorectal cancer", Int J Clin Exp Pathol, 8, pp.7112~7121 (2015)
25. Coates RF, "Significance of positive and inhibitory regulators in the TGF-beta signaling pathway in colorectal cancers", Hum Pathol, 66, pp.34~39 (2017)
26. Xie W, "Loss of Smad signaling in human colorectal cancer is associated with advanced disease and poor prognosis", Cancer J, 9, pp.302~312 (2003)
27. Gulubova M, "Role of TGF-beta1, its receptor TGFbetaRII, and Smad proteins in the progression of colorectal cancer", Int J Colorectal Dis, 25, pp.591~599 (2010)
28. Chun HK, "Low expression of transforming growth factor beta-1 in cancer tissue predicts a poor prognosis for patients with stage III rectal cancers", Oncology, 86, pp.159~169 (2014)
29. Voorneveld PW, "A Meta-analysis of SMAD4 immunohistochemistry as a prognostic marker in colorectal cancer", Transl Oncol, 8, pp.18~24 (2015)
30. Zhang B, "Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway", Br J Cancer, 110, pp.946~957 (2014)
31. Voorneveld PW, "The BMP pathway either enhances or inhibits the Wnt pathway depending on the SMAD4and p53 status in CRC", Br J Cancer, 112, pp.122~130 (2015)
32. Chow E, "A review of juvenile polyposis syndrome", J Gastroenterol Hepatol, 20, pp.1634~1640 (2005)
33. Ahn BK, "Smad4 may help to identify a subset of colorectal cancer patients with early recurrence after curative therapy", Hepatogastroenterology, 58, pp.1933~1936 (2011)
34. Bae JM, "Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system", Br J Cancer, 116, pp.1012~1020 (2017)
35. Bankhead P, "QuPath : open source software for digital pathology image analysis", Sci Rep, 7, pp.16878~ (2017)
36. Bae JM, "Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients", World J Gastroenterol, 21, pp.1457~1467 (2015)
37. Boland CR, "A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer", Cancer Res, 58, pp.5248~5257 (1998)
38. Weisenberger DJ, "CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer", Nat Genet, 38, pp.787~793 (2006)
39. Jung B, "Transforming growth factor beta superfamily signaling in development of colorectal cancer", Gastroenterology, 152, pp.36~52 (2017)
40. Salovaara R, "Frequent loss of SMAD4", DPC4 protein in colorectal cancers, 2002, pp.51, 56~59
41. Ilyas M, "Transforming growth factor beta stimulation of colorectal cancer cell lines : type II receptor bypass and changes in adhesion molecule expression", Proc Natl Acad Sci U S A, 96, pp.3087~3091 (1999)
42. Deacu E, "Activin type II receptor restoration in ACVR2-deficient colon cancer cells induces transforming growth factor-beta response pathway genes", Cancer Res, 64, pp.7690~7696 (2004)
43. Baker K, "Microsatellite unstable colorectal cancer cell lines with truncating TGFbetaRII mutations remain sensitive to endogenous TGFbeta", J Pathol, 213, pp.257~265 (2007)
44. de Miranda NF, "Transforming growth factor beta signaling in colorectal cancer cells with microsatellite instability despite biallelic mutations in TGFBR2", Gastroenterology, 148, pp.1427.e8~1437.e8 (2015)
45. Barros R, "Key elements of the BMP", SMAD pathway co-localize with CDX2 in intestinal metaplasia and regulate CDX2 expression in human gastric cell lines, 2008, pp.215, 411~420
46. Barros R, "Juvenile polyps have gastric differentiation with MUC5AC expression and downregulation of CDX2 and SMAD4", Histochem Cell Biol, 131, pp.765~772 (2009)
47. Savagner P., "The epithelial-mesenchymal transition (EMT) phenomenon", Ann Oncol, 21(Suppl 7), pp.vii89~vii92 (2010)
48. Ioannou M, "Smad4 and epithelial-mesenchymal transition proteins in colorectal carcinoma : an immunohistochemical study", J Mol Histol, 49, pp.235~244 (2018)
49. Deckers M, "The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells", Cancer Res, 66, pp.2202~2209 (2006)
50. Itatani Y, "Loss of SMAD4 from colorectal cancer cells promotes CCL15 expression to recruit CCR1+ myeloid cells and facilitate liver metastasis", Gastroenterology, 145, pp.1064.e11~1075.e11 (2013)
51. Inamoto S, "Loss of SMAD4 promotes colorectal cancer progression by accumulation of myeloid-derived suppressor cells through the CCL15-CCR1 chemokine axis", Clin Cancer Res, 22, pp.492~501 (2016)
52. Yamamoto T, "Loss of SMAD4 promotes lung metastasis of colorectal cancer by accumulation of CCR1+ tumorassociated neutrophils through CCL15-CCR1 axis", Clin Cancer Res, 23, pp.833~844 (2017)

관련 논문AI추천